Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.21 -0.36 (-1.94%)

Delayed Quote Updated: 10:44 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

What Does the Market Think About Legend Biotech? ↗

April 03, 2025

Via Benzinga

Demystifying Legend Biotech: Insights From 5 Analyst Reviews ↗

March 17, 2025

Via Benzinga

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

March 11, 2025

From Legend Biotech USA Inc.

Via GlobeNewswire

Is Legend Biotech Gaining or Losing Market Support? ↗

March 05, 2025

Via Benzinga

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

February 25, 2025

From Legend Biotech USA Inc.

Via GlobeNewswire

Peering Into Legend Biotech's Recent Short Interest ↗

February 17, 2025

Via Benzinga

Where Legend Biotech Stands With Analysts ↗

January 23, 2025

Via Benzinga

Breaking Down Legend Biotech: 9 Analysts Share Their Views ↗

December 30, 2024

Via Benzinga

Earnings Scheduled For March 11, 2025 ↗

March 11, 2025

Via Benzinga

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 19, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

(LEGN) - Analyzing Legend Biotech's Short Interest ↗

December 16, 2024

Via Benzinga

Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings) ↗

December 10, 2024

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

December 09, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

November 12, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

November 07, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

9 Analysts Have This To Say About Legend Biotech ↗

October 16, 2024

Via Benzinga

Where Legend Biotech Stands With Analysts ↗

September 27, 2024

Via Benzinga

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

November 05, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

November 04, 2024

Newly created position to lead efforts focused on continued growth and sales

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

October 24, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

Peering Into Legend Biotech's Recent Short Interest ↗

September 06, 2024

Via Benzinga

Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock ↗

August 28, 2024

Via Benzinga

Looking Into Legend Biotech's Recent Short Interest ↗

August 16, 2024

Via Benzinga

Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock ↗

August 12, 2024

Via Benzinga

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

October 03, 2024

New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leader

From Legend Biotech USA Inc.

Via GlobeNewswire

Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients ↗

September 30, 2024

Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by...

Via Benzinga

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

September 27, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma ↗

September 27, 2024

Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma.

Via Investor's Business Daily

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 20, 2024

From Legend Biotech USA Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.